

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **April 28, 2017**

JAGUAR ANIMAL HEALTH, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation)

001-36714
(Commission File Number)

46-2956775
(IRS Employer Identification No.)

**201 Mission Street, Suite 2375
San Francisco, California**
(Address of principal executive offices)

94105
(Zip Code)

Registrant's telephone number, including area code: **(415) 371-8300**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events.

On April 28, 2017, Jaguar Animal Health, Inc. ("Jaguar") issued a press release announcing its entry into an exclusive distribution agreement with JP Equine Services for distribution of Jaguar's lead non-prescription products, Neonorm™ Foal and Neonorm™ Calf in Japan. The press release also contained information regarding the determination by the NASDAQ Hearing Panel to grant Jaguar's request for continued listing on NASDAQ, subject to completion of Jaguar's proposed merger with Napo Pharmaceuticals, Inc. on or before July 31, 2017 and Jaguar's compliance with NASDAQ's \$2.5 million stockholders' equity requirement as a result of the merger.

A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

Disclaimer on Forward-looking Statements

This Current Report on Form 8-K, including the press release, contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. These include statements regarding the completion of Jaguar's proposed merger with Napo

Pharmaceuticals, Inc. on or before July 31, 2017, Jaguar's ability to timely evidence compliance with the terms of the Panel's decision, Jaguar's intention to develop species-specific formulations of Neonorm™ in additional target species, and Jaguar's plan to develop formulations of Canalevia™ for cats, horses and dogs. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Jaguar Animal Health, Inc. Press Release dated April 28, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

JAGUAR ANIMAL HEALTH, INC.

By: /s/ Karen S. Wright
Name: Karen S. Wright
Title: Chief Financial Officer

Date: May 2, 2017



Jaguar Signs Distribution Agreement for Japan for Neonorm Foal & Neonorm Calf

Jaguar Receives Extension of Nasdaq Listing

San Francisco, CA (April 28, 2017): Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, today announced that it has signed an exclusive distribution agreement with JP Equine Services for distribution of Jaguar’s lead non-prescription products, Neonorm™ Foal and Neonorm™ Calf, in Japan.

Neonorm™ Foal is a natural, clinically-tested, non-drug product designed for use as an anti-diarrheal in newborn horses. Diarrhea is one of the most common clinical complaints in foals, especially within the first 30 days of life. The crippling effects of dehydration that often result from secretory diarrhea in foals can manifest quickly, precipitate adverse health effects and lead to death. Neonorm™ Calf has been formulated and clinically tested to help proactively retain fluid in dairy calves and reduce the severity of diarrhea—aiding calves in avoiding debilitating, dangerous levels of dehydration associated with scours.

In the year 2,000, there were an estimated 115,000 horses in Japan¹—a country where more than 21,000 horse races are held annually. According to the Japan Dairy Council, there were an estimated 1,450,000 dairy cattle in Japan in 2012, spread across 20,100 dairy farms. Although dairy products have traditionally not represented a large portion of the Japanese diet, increases in disposable income in recent years have led to an increased interest in foreign products and growth in the intake of dairy.²

Headquartered in Jamaica, NY and established in 2001, JP Equine Services began as a shipping company handling transport of thoroughbred racehorses to Japan, Korea, Saudi Arabia and Italy. The company later expanded into distribution of equine products to breeding farms and veterinary practices throughout the world.

“We’re very excited to represent Neonorm™ Foal and Neonorm™ Calf in Japan and look forward to a successful relationship with Jaguar Animal Health,” commented Jimmy Preziosi, founder of JP Equine Services.

Henry Schein, Inc., the world’s largest provider of health care products and services to office-based dental, animal health and medical practitioners, continues to serve as Jaguar’s exclusive distributor of Neonorm™ Foal in the U.S. equine market.

Extension of Nasdaq Listing

Jaguar also announced today that, on April 27, 2017, the Company was notified that the Nasdaq Hearings Panel (the “Panel”) determined to grant the Company’s request for continued listing on Nasdaq. The Company’s continued listing is subject to the completion of Jaguar’s proposed merger with Napo Pharmaceuticals, Inc. on or before July 31, 2017, and the Company’s compliance with Nasdaq’s \$2.5 million stockholders’ equity requirement as a result of the merger. The Company is diligently working to timely evidence compliance with the terms of the Panel’s decision. The decision follows the Company’s recent hearing before the Panel, at which it presented its plan to evidence compliance with the stockholders’ equity requirement concurrent with the merger.

About Jaguar Animal Health, Inc.

Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses. Canalevia™ is Jaguar’s lead prescription drug product candidate, intended for the treatment of various forms of diarrhea in dogs. Equilevia™ (formerly referred to as SB-300) is Jaguar’s prescription drug product candidate for the treatment of gastrointestinal ulcers in horses. Canalevia™ and Equilevia™ contain ingredients isolated and purified from the *Croton lechleri* tree, which is sustainably harvested. Neonorm™ Calf and Neonorm™ Foal are the Company’s lead non-prescription products. Neonorm™ is a standardized botanical extract derived from the *Croton lechleri* tree. Canalevia™ and Neonorm™ are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar has nine active investigational new animal drug applications, or INADs, filed with the FDA and intends to develop species-specific formulations of Neonorm™ in six additional target species, formulations of Equilevia™ in horses, and Canalevia™ for cats and dogs.

For more information about Jaguar, please visit www.jaguaranimalhealth.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the completion of Jaguar’s proposed merger with Napo Pharmaceuticals, Inc. on or before July 31, 2017, the Company’s ability to timely evidence compliance with the terms of the Panel’s decision, Jaguar’s intention to develop species-specific formulations of Neonorm™ in additional target species, and the Company’s plan to develop formulations of Canalevia™ for cats, horses and dogs. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

¹A. Fotovati1, Y. Mizuno, T. Ito and H. Moriyama, A Statistical Study of the Horse Industry in Japan, Asian-Aus. J. Anim. Sci. 13 Supplement July 2000 C: 403

Source: Jaguar Animal Health, Inc.

Contact:

Garth Russell
KCSA Strategic Communications
P: 212-896-1250
grussell@kcsa.com

Jaguar-JAGX
